Our experienced team of pharmacoeconomists specializes in conducting Budget Impact Analysis (BIA) and Cost-effectiveness Studies (CES). Through BIA, we assess the financial implications of introducing new therapies or healthcare interventions within a specific healthcare system or organization. Our analyses provide decision-makers with a comprehensive understanding of the budgetary impact, including costs, cost-savings, and potential financial consequences.
We utilize advanced modeling techniques, including Markov modeling, decision trees, and simulation modeling, to simulate long-term outcomes and assess the cost-effectiveness of interventions over time. Our analyses incorporate various factors, such as treatment costs, patient outcomes, quality-adjusted life years (QALYs), and other relevant metrics, to provide a comprehensive economic evaluation.
At Phoenix CR, we understand the importance of presenting complex pharmacoeconomic analyses in a clear and concise manner. Our reports and presentations are tailored to the needs of decision-makers, presenting the findings in an easily understandable format. We work closely with our clients, ensuring that the results align with their specific requirements and are presented in a way that facilitates informed decision-making.